Shawn Kile, MD
Neurology · Sacramento, CANPI 1831170844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. That places this record below the midpoint for neurology clinicians in CA, where the typical reported total is $885.
Across 2 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$16
- AbbVie$13
Across 96 payments — averaging $4833.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$159K
- Genentech, Inc.$156K
- Alnylam Pharmaceuticals Inc.$146K
- Merck$3K
What the payments were for
- Food & beverage$29100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 1 | $16 |
| AbbVie | 1 | $13 |
How this compares
$29 in reported general payments places this provider in the 10th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 471 | $49,931 |
| Memantine Hcl ErMemantine Hcl | 443 | $37,443 |
| Rivastigmine | 95 | $22,521 |
| Lacosamide | 62 | $13,397 |
| ExelonRivastigmine | 16 | $11,380 |
| Memantine Hcl | 297 | $11,070 |
| Galantamine Hbr | 114 | $7,407 |
| Levetiracetam ErLevetiracetam | 63 | $5,049 |
| Donepezil Hcl | 342 | $3,856 |
| Quetiapine Fumarate | 177 | $2,484 |
| Levetiracetam | 35 | $2,462 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 97 | $1,849 |
| Escitalopram Oxalate | 100 | $1,449 |
| Trazodone Hcl | 172 | $1,293 |
| RivastigmineRivastigmine Tartrate | 22 | $1,176 |
Paid to pharmacies, not to this prescriber.
Other neurology in Sacramento
- Lin ZhangSacramento$328K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.